Full Event Guide

Gene Therapy for Ophthalmic Disorders is your year’s only comprehensive guide to:

  • Define relevant preclinical and clinical endpoints
  • Explore novel routes of administration to the front and back of the eye
  • Improve the translatability piece of your preclinical model work

Having trouble downloading the brochure? Let us know and we’ll email it to you instead

Samarendra Mohanty - Nanoscope (002)

“I am excited as I have found in last meeting that this is a unique group of focused, highly experienced diverse set of professionals working to make ocular gene therapy available to patients.”

Samarendra Mohanty, Chief Scientific Officer & President, Nanoscope Therapeutics     

A snapshot of the program:









Hours of Networking

New Speaking Companies

Conference Days

Deep-Dive Interactive Workshops

Top 5 Reasons to Attend!

Untitled design (15)

Uncover novel methods of capsid engineering with Atsena Therapeutics, ViGeneron and IVERIC Bio, showing the next generation of vector development

Untitled design (16)

Engage in three, expert-lead workshops that will explore non-viral delivery modalities and biomarkers for ophthalmic gene therapy with workshop leaders from Novartis, Intergalactic Therapeutics & Nanoscope

Untitled design (17)

Hear from Daniel Chung at SparingVision, on how to develop an effective patient outreach program that ensures patient comprehension and input in clinical development

Untitled design (18)

Explore the use of immunosuppressants and anti-inflammtory agents in aiding preclinical safety data with Janssen, Northern Biomedical Research & Novartis

Untitled design (19)

Discover the next generation of technology and devices being used in the delivery of ophthalmic gene therapy from Clearside Biomedical, REGENXBIO, University of Oxford and Everads Therapy during our highly anticipated postconference delivery day